These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The pros and cons of plasmapheresis therapy carried out on time. Izquierdo-Ortiz MJ; Mercado-Valdivia V; Camarero-Temiño V; Hijazi-Prieto B; Saiz-Calero I; Angola-Muquel MC; Muñoz-Merino M; Rodríguez-Velasco B; Abaigar-Luquin P Nefrologia; 2013; 33(5):741-2. PubMed ID: 24089171 [No Abstract] [Full Text] [Related]
5. Renal protection: progression, regression, remission from nephropathy beyond blood pressure control. Remuzzi G Int J Clin Pract Suppl; 2000 May; (110):9-15. PubMed ID: 10912302 [No Abstract] [Full Text] [Related]
6. Diagnostic accuracy of the protein/creatinine ratio in urine samples to estimate 24-h proteinuria in patients with primary glomerulopathies: a longitudinal study. Antunes VV; Veronese FJ; Morales JV Nephrol Dial Transplant; 2008 Jul; 23(7):2242-6. PubMed ID: 18281321 [TBL] [Abstract][Full Text] [Related]
7. REIN on obesity, proteinuria and CKD. Choi ME J Am Soc Nephrol; 2011 Jun; 22(6):990-2. PubMed ID: 21617125 [No Abstract] [Full Text] [Related]
8. Halting the progression of renal disease: where we stand? Campbell RC; Remuzzi G Nefrologia; 2002; 22(4):303-5. PubMed ID: 12369119 [No Abstract] [Full Text] [Related]
9. Effects of different converting-enzyme inhibitors on the course of non-diabetic glomerulopathies. Bernheim J Nephrol Dial Transplant; 1990; 5(10):837-40. PubMed ID: 2128376 [No Abstract] [Full Text] [Related]
10. The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises. Schieppati A; Remuzzi G Kidney Int; 2003 Dec; 64(6):1947-55. PubMed ID: 14633117 [No Abstract] [Full Text] [Related]
11. Proteinuria in special populations: pregnant women and children. Hladunewich MA; Schaefer F Adv Chronic Kidney Dis; 2011 Jul; 18(4):267-72. PubMed ID: 21782133 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic measures in proteinuric nephropathy. Praga M Kidney Int Suppl; 2005 Dec; (99):S137-41. PubMed ID: 16336567 [TBL] [Abstract][Full Text] [Related]
14. Are two better than one? Angiotensin-converting enzyme inhibitors plus angiotensin receptor blockers for reducing blood pressure and proteinuria in kidney disease. Linas SL Clin J Am Soc Nephrol; 2008 Jan; 3 Suppl 1(Suppl 1):S17-23. PubMed ID: 18178792 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic concepts of proteinuria and intra-glomerular hypertension. Woo KT Singapore Med J; 1998 Jun; 39(6):271-2. PubMed ID: 9803817 [No Abstract] [Full Text] [Related]
16. Proteinuria and microalbuminuria in adults: significance, evaluation, and treatment. Venkat KK South Med J; 2004 Oct; 97(10):969-79. PubMed ID: 15558924 [TBL] [Abstract][Full Text] [Related]
17. ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. Remuzzi A; Gagliardini E; Sangalli F; Bonomelli M; Piccinelli M; Benigni A; Remuzzi G Kidney Int; 2006 Apr; 69(7):1124-30. PubMed ID: 16395266 [TBL] [Abstract][Full Text] [Related]
18. Angiotensin blockade as sole treatment for proteinuric kidney disease in children. Chandar J; Abitbol C; Montané B; Zilleruelo G Nephrol Dial Transplant; 2007 May; 22(5):1332-7. PubMed ID: 17299000 [TBL] [Abstract][Full Text] [Related]
19. Research into the glomerular podocyte--is it relevant to diabetic nephropathy? White KE Diabet Med; 2006 Jul; 23(7):715-9. PubMed ID: 16842474 [TBL] [Abstract][Full Text] [Related]
20. Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. Tahir H; Jackson LL; Warnock DG J Am Soc Nephrol; 2007 Sep; 18(9):2609-17. PubMed ID: 17656478 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]